Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues.

Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates.

Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.

Key Stats

• Today's Range: $2.25 to $2.39
• 50-Day Range: $1.82 to $4.15
• 52-Week Range: $1.00 to $5.22
• Volume: 57,227 shs
• Average Volume: 130,336 shs
• Market Capitalization: $61.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Celularity Stock Analysis - MarketRank™

Celularity scored higher than 34% of companies evaluated by MarketBeat, and ranked 812th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Celularity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Celularity has a consensus price target of $6.00, representing about 158.6% upside from its current price of $2.32.

Amount of Analyst Coverage

Celularity has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Celularity is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celularity is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celularity has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.33% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Celularity has recently increased by 3.68%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celularity does not currently pay a dividend.

Dividend Growth

Celularity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.33% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Celularity has recently increased by 3.68%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.82

News Sentiment

Celularity has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Celularity this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celularity insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.02% of the stock of Celularity is held by institutions.

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed this year?

Celularity's stock was trading at $2.08 at the start of the year. Since then, CELU shares have increased by 11.5% and is now trading at $2.32.

How were Celularity's earnings last quarter?

Celularity, Inc. (NASDAQ:CELU) posted its quarterly earnings data on Friday, August, 29th. The company reported ($1.02) EPS for the quarter. The company earned $5.74 million during the quarter. Celularity had a negative net margin of 165.22% and a negative trailing twelve-month return on equity of 459.57%.

When did Celularity's stock split?

Celularity's stock reverse split on Thursday, February 29th 2024.The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Celularity's major shareholders?

Top institutional shareholders of Celularity include Valmark Advisers Inc. (0.21%), Bank of America Corp DE (0.16%), XTX Topco Ltd (0.09%) and Simplex Trading LLC. Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celularity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/29/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Celularity: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +158.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.89 million
• Net Margins: -165.22%
• Pretax Margin: -165.21%
• Return on Equity: -459.57%
• Return on Assets: -57.71%

Debt

• Debt-to-Equity Ratio: 4.07
• Current Ratio: 0.25
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $54.22 million
• Price / Sales: 1.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 6.27

Miscellaneous

• Outstanding Shares: 26,690,000
• Free Float: 20,792,000
• Market Cap: $61.92 million
• Optionable: Optionable
• Beta: 0.81